Fundraising Fox
Corbus Pharmaceuticals
NASDAQ: CRBPNew York, US · Founded 2013 · 1 known investors
Find your way into Corbus Pharmaceuticals
Each arrow is one introduction. Sign up to fill in the first one.
12 people can intro you to Yuval
Ask Brent Pfeiffenberger to introduce you to Yuval Cohen
You →Brent · together at Corbus Pharmaceuticals →Yuval
Sign up to find every way you can get introduced to Corbus Pharmaceuticals
- Your email: who you already know at Corbus Pharmaceuticals, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Corbus Pharmaceuticals team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Corbus Pharmaceuticals is a biopharmaceutical company developing therapies for critical stages of clinical development, with a focus on advancing patient-centered progress in drug development. The company is led by a senior leadership team with expertise in pharmaceutical research, regulatory affairs, and clinical development.
Founders & leadership
Corbus Pharmaceuticals was founded in 2013 by Yuval Cohen.
YC
Yuval CohenChief Executive Officer and DirectorYuval Cohen is Chief Executive Officer and Director of Corbus Pharmaceuticals, a biopharmaceutical company in clinical development. He has background in drug discovery and development, with experience in anti-inflammatory, oncology, and obesity therapeutics.
Board
DH
JB
John BrancaccioBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$6.4M disclosed across 3 of 4 rounds · 1900–2014
▶$6.3MraisedApr 2014 · 45 investors · InvestingRule 506(b)
▶$6.3MraisedApr 2014 · 45 investors · Investing
Rule 506(b)Officers, directors & promoters on the filing
- Robert ZurierExecutive Officer
- Yuval CohenExecutive Officer, Director
- Alan HolmerDirector
- Sean MoranExecutive Officer
- David HochmanDirector
- Mark TepperExecutive Officer
- Offering amount
- $13M
- Amount sold
- $6.3M
- Sales commissions
- $1.3M
- Placement agents
- Aegis Capital Corp.
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$19.8KraisedMar 2014 · 3 investors · InvestingRule 506(b)
▶$19.8KraisedMar 2014 · 3 investors · Investing
Rule 506(b)Officers, directors & promoters on the filing
- John BrancaccioExecutive Officer
- David HochmanExecutive Officer, Director
- Offering amount
- $30K
- Amount sold
- $19.8K
- First sale
- Mar 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$90KraisedJan 2014 · 19 investors · InvestingRule 506(b)
▶$90KraisedJan 2014 · 19 investors · Investing
Rule 506(b)Officers, directors & promoters on the filing
- David HochmanExecutive Officer, Director
- John BrancaccioExecutive Officer
- Offering amount
- $90K
- Amount sold
- $90K
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$25.8Mvaluation at IPOOct 2014 · $1.00/share · S-1/A
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
2 people who came through Corbus Pharmaceuticals went on to found or lead other companies.
Related companies · 8
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
TipRanksFinancial analysis and stock research platform.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies working in the same space as Corbus Pharmaceuticals.
Frequently asked questions
- What does Corbus Pharmaceuticals do?
- Corbus Pharmaceuticals is a biopharmaceutical company developing therapies for critical stages of clinical development, with a focus on advancing patient-centered progress in drug development. The company is led by a senior leadership team with expertise in pharmaceutical research, regulatory affairs, and clinical development.
- Who founded Corbus Pharmaceuticals?
- Corbus Pharmaceuticals was founded by Yuval Cohen in 2013.
- Who are Corbus Pharmaceuticals's investors?
- Corbus Pharmaceuticals's investors include Boston Harbor Angels.
- How much funding has Corbus Pharmaceuticals raised?
- Corbus Pharmaceuticals has disclosed $6.4M raised across 3 of its 4 known rounds.
- Where is Corbus Pharmaceuticals headquartered?
- Corbus Pharmaceuticals is headquartered in New York, US.